Table 1 CDC42-mediated relative mAb-titer increase over native clone titers. The clones represent five different products.
From: Biosynthetic pathway deflection – a new cell line engineering approach
Titers of Naïve mAb producing clones [g/l] | Titers of cdc42-engineered mAb producing clones [g/l] | Relative Fold Increase per modified clone |
|---|---|---|
0,8 | 1,65 | 2,06 |
0,9 | 2,2 | 2,4 |
2,3 | 3,0 | 1,3 |
2,6 | 4,5 | 1,73 |
0,8 | 1,65 | 2,06 |